#Canada #Cambridge #PrimeC #ALS Treatment #NeuroSense Therapeutics

NeuroSense's Significant Milestone in ALS Treatment Development

NeuroSense Therapeutics Ltd., a prominent player in the biotechnology sector, is making notable strides towards a New Drug Submission (NDS) for its leading candidate, PrimeC, aimed at addressing amyotrophic lateral sclerosis (ALS). Following the successful conclusion of the Pre-NDS process with Health Canada, NeuroSense is setting its sights on a December 2026 filing date. This follows productive discussions which confirmed the alignment between the company's submission framework and Health Canada’s expectations.

CEO Alon Ben-Noon emphasized the importance of this alignment, stating, "We now have an alignment with the Canadian regulator and a clear operational target." This highlights the company's commitment to advancing essential treatments for neurodegenerative diseases at a time when options remain scarce, especially for conditions as debilitating as ALS.

The Need for Effective ALS Treatments

The urgency for better treatments for ALS is driven by shocking statistics. Current estimates suggest that over 3,000 Canadians are living with this aggressive disease, with around 1,000 new diagnoses occurring each year. As it stands, the treatment landscape is limited primarily to riluzole and edaravone, therapies that provide minimal benefits but come at a hefty annual cost of approximately CAD 120,000. This stark reality underscores the enormous healthcare burden posed by ALS and the pressing demand for more effective therapeutic options.

PrimeC: A Game-Changer in ALS Therapy

NeuroSense's PrimeC is designed as a multi-action therapy that targets critical aspects of neurodegenerative progression. By utilizing a combination of two FDA-approved medications—ciprofloxacin and celecoxib—PrimeC aims to address key mechanisms such as neuroinflammation and oxidative stress. Recent trials, namely the Phase 2b PARADIGM clinical program, have yielded promising results, showcasing significant long-term clinical benefits including a notable 15-month survival increase for patients.

The positive outcomes from the PARADIGM study include achieved primary biomarker endpoints and consistent findings across several relevant biological pathways. These results form the backbone of the upcoming NDS, which, if approved, could revolutionize the treatment landscape for ALS patients.

Moving Forward with Confidence

NeuroSense is also preparing for its next major step—the Phase 3 clinical trial, dubbed PARAGON, set to evaluate PrimeC further in a larger patient cohort. With approximately 300 participants expected, this trial will be pivotal in confirming the efficacy of PrimeC before it moves closer to a commercial release.

As the December 2026 target approaches, NeuroSense urges the healthcare community and stakeholders to recognize the critical importance of sustained investment and focus in developing treatment avenues for ALS. Leveraging the regulatory greenlight, NeuroSense is confident about taking its next steps, aiming not only to meet regulatory demands but more importantly to transform the lives of those afflicted by this devastating disease.

For continued updates and further insights into NeuroSense's mission to combat ALS and other neurodegenerative diseases, interested parties can follow the company on its official website and through various social media platforms.